Millennium Pharmaceuticals News

Download this week's review of health-care investments or listen below. Baiju Shah Two major health-care investments from last week are perfect cases of investors trusting in the management teams over the ...

Teenagers from two schools visited the Centre for Mathematical Sciences this week to show how they'd unearthed valuable data on disease dynamics during a nine-month research initiative organised by the ...

Ore Pharmaceuticals Inc. has filed an application to begin testing its first drug compound in humans.

A Cape Cod Notebook 6/24/08 Millennium Grove II BY Robert Finch Last week I described my attempts to locate "Millennium Grove," the 19th century Methodist meeting campground in North Eastham that was described ...

Takeda Pharmaceutical Co. , Japan's biggest drugmaker, won U.S. approval to expand marketing of Velcade for patients with the blood cancer multiple myeloma.

Despite industry challenges, savvy chemists can still land jobs along R&D pipeline Susan J. Ainsworth "It's certainly an interesting time in the pharmaceutical and biotechnology recruiting business right now," ...

Francis Collins , who led the U.S. government effort to create a detailed blueprint of the human genetic code, will step down Aug.

Carbon 12 is a major new work from Welsh National Opera tracing the impact of coal on a nation's economy and identity.

The Scientist, magazine of the life sciences, announced today the winners of its 6th annual Best Places to Work in Industry survey .

Alnylam Pharmaceuticals Inc. has struck a deal with Japanese drug maker Takeda Pharmaceutical Co.

Among the companies whose shares are expected to see active trade in Friday's session are Abercrombie & Fitch, FairPoint Communications, and Millennium Pharma. via MarketWatch

The April announcement that Japanese drug maker Takeda Pharmaceutical would buy Massachusetts-based Millennium Pharmaceuticals for $8.8 billion sent Millennium shares markedly higher. via Seeking Alpha

Takeda Pharmaceutical Co. said Friday it is likely to post a year-on-year drop in group operating profit for the second straight year in fiscal 2008 due to rising expenses including a string of acquisitions. via Med Ad News

“There are some in the market who view the premium we paid as a little too high, there are others who see our strategy as sound and the price reasonable. I think the view in the market is still fluid”

Japan's Takeda Pharmaceutical Co Ltd posted a 77 percent drop in quarterly operating profit on Friday, and forecast a sharp fall in annual income on costs for its $8.8 billion purchase of U.S. biotech firm ... via Reuters

Standard & Poor's will make the following changes to the S&P MidCap 400 and S&P SmallCap 600: -- DreamWorks Animation SKG Inc. via Huliq.com

“You're taking one-quarter to one-third of potential buyers out of the market because they can't finance these deals”

For all the talk of a liquidity crunch on Wall Street, you might expect to see mergers and acquisitions come to a screeching halt. via Investor's Business Daily

Unlike the dramatic and acrimonious activist shareholder battles at other drugmakers, Endo Pharmaceuticals recently went through a friendlier version of a shareholder revolt. via Motley Fool

OSAKA, Japan, and CAMBRIDGE, Mass., April 29, 2008 /PRNewswire-FirstCall/ -- Takeda Pharmaceutical Company Limited and Millennium Pharmaceuticals, Inc. via Med Ad News

“It needs some good news to break out. The trials [aren't] far enough along.”

Think of investor sentiment as a pendulum that swings in tandem with a company's share price. via The Motley Fool

“It does suggest that the field and the industry sees this as very promising”

Mass High Tech: The Journal of New England Technology - by Ryan McBride Mass High Tech Epigenetics. via Bizjournals